These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 19117960)

  • 1. Catheter-related thrombosis: biological and clinical evidence for risk with currently available anticoagulants.
    Montalescot G; Walenga JM
    Clin Appl Thromb Hemost; 2009; 15(2):183-96. PubMed ID: 19117960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
    Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
    Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
    Mehta SR; Granger CB; Eikelboom JW; Bassand JP; Wallentin L; Faxon DP; Peters RJ; Budaj A; Afzal R; Chrolavicius S; Fox KA; Yusuf S
    J Am Coll Cardiol; 2007 Oct; 50(18):1742-51. PubMed ID: 17964037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.
    Montalescot G; Cohen M; Salette G; Desmet WJ; Macaya C; Aylward PE; Steg PG; White HD; Gallo R; Steinhubl SR;
    Eur Heart J; 2008 Feb; 29(4):462-71. PubMed ID: 18276619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fondaparinux: an overview.
    Nadar SK; Goyal D; Shantsila E; Banerjee P; Lip GY
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):577-85. PubMed ID: 19505272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug insight: bleeding after percutaneous coronary intervention-risks, measures and impact of anticoagulant treatment options.
    Rothman MT
    Nat Clin Pract Cardiovasc Med; 2005 Sep; 2(9):465-74. PubMed ID: 16265587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial.
    White HD; Gallo R; Cohen M; Steg PG; Aylward PE; Bode C; Steinhubl S; Montalescot G
    Am Heart J; 2009 Jan; 157(1):125-31. PubMed ID: 19081408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis.
    Borentain M; Montalescot G; Bouzamondo A; Choussat R; Hulot JS; Lechat P
    Catheter Cardiovasc Interv; 2005 Jun; 65(2):212-21. PubMed ID: 15900551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of anticoagulation regimens on sheath management and bleeding in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial.
    Gallo R; Steinhubl SR; White HD; Montalescot G;
    Catheter Cardiovasc Interv; 2009 Feb; 73(3):319-25. PubMed ID: 19213086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of anticoagulants in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention: a potential role for enoxaparin.
    Christy GW
    J Invasive Cardiol; 2008 Nov; 20(11):615-21. PubMed ID: 18987403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Easing the economic burden of acute coronary syndromes: cost-effectiveness of emerging therapies.
    Nutescu EA
    Am J Manag Care; 2006 Dec; 12(16 Suppl):S444-50. PubMed ID: 17203989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical issues on the use of enoxaparin in elective and emergent percutaneous coronary intervention.
    Díez JG
    J Invasive Cardiol; 2008 Sep; 20(9):482-9. PubMed ID: 18762681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro comparison of fondaparinux, unfractionated heparin, and enoxaparin in preventing cardiac catheter-associated thrombus.
    Schlitt A; Rupprecht HJ; Reindl I; Schubert S; Hauroeder B; Carter JM; Peetz D; Kropff SS; Maegdefessel L; Russ M; Schmidt H; Ebelt H; Werdan K; Buerke M
    Coron Artery Dis; 2008 Jun; 19(4):279-84. PubMed ID: 18480673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enoxaparin experience in percutaneous coronary intervention.
    Somani V; Trivedi S
    J Indian Med Assoc; 2008 Jan; 106(1):12-5. PubMed ID: 18705262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive pharmacologic therapy in percutaneous coronary intervention: part II anticoagulant therapy.
    Kim SJ; Giugliano RP; Jang IK
    Coron Artery Dis; 2011 Mar; 22(1):113-21. PubMed ID: 21304293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging anticoagulants: mechanism of action and future potential.
    Klement P; Rak J
    Vnitr Lek; 2006 Mar; 52 Suppl 1():119-22. PubMed ID: 16637459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective multicentre observational study on the management of patients on oral anticoagulation undergoing coronary artery stenting: rationale and design of the ongoing warfarin and coronary stenting (WAR-STENT) registry.
    Rubboli A; Bolognese L; Di Pasquale G; Galvani M; La Vecchia L; Maggioni AP
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):200-3. PubMed ID: 19377385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.